Variations in the INS component of the INS-IGF2 gene can significantly alter how patients respond to insulin therapies used in diabetes management, affecting dosing requirements and the risk of hypoglycemia or insulin resistance. Meanwhile, polymorphisms in the IGF2 portion may influence the effectiveness of cancer therapies that target the IGF pathway, crucial for cell proliferation and resistance to apoptosis in numerous cancers and some growth disorders.